Future Of British Business
GSK to Buy Asthma Drug Owner Aiolos for Up to $1.4 Billion
- Aiolos has promising asthma drug entering mid-stage tests
- UK drugmaker will pay $1 billion upfront, rest in milestones
This article is for subscribers only.
GSK Plc agreed to buy the closely held US biotech Aiolos Bio Inc., spending as much as $1.4 billion to gain a promising respiratory medicine.
Aiolos has an experimental drug ready to enter mid-stage tests for adults with asthma, although the monoclonal antibody has potential in other diseases related to inflammation such as chronic rhinosinusitis and nasal polyps, GSK said Tuesday.